Free Trial

179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC

Zevra Therapeutics logo with Medical background

Propel Bio Management LLC bought a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 179,874 shares of the company's stock, valued at approximately $1,248,000. Zevra Therapeutics makes up about 0.7% of Propel Bio Management LLC's portfolio, making the stock its 15th biggest position. Propel Bio Management LLC owned 0.34% of Zevra Therapeutics as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $474,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock worth $201,000 after purchasing an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $833,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Zevra Therapeutics in the 1st quarter worth approximately $64,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company's stock worth $9,883,000 after purchasing an additional 58,866 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Stock Down 0.6 %

NASDAQ ZVRA traded down $0.06 during trading on Tuesday, reaching $9.43. The company's stock had a trading volume of 402,332 shares, compared to its average volume of 550,276. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $503.37 million, a PE ratio of -4.82 and a beta of 1.93. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76. The business has a 50-day moving average price of $8.22 and a 200-day moving average price of $6.69.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the company posted ($0.40) earnings per share. On average, research analysts forecast that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZVRA has been the topic of several recent analyst reports. Maxim Group lifted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Roth Mkm lifted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. William Blair upgraded Zevra Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of "Buy" and an average price target of $21.00.

Read Our Latest Stock Report on Zevra Therapeutics

Zevra Therapeutics Company Profile

(Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Read More

Institutional Ownership by Quarter for Zevra Therapeutics (NASDAQ:ZVRA)

→ First JFK… next Elon? (From Porter & Company) (Ad)

Should you invest $1,000 in Zevra Therapeutics right now?

Before you consider Zevra Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.

While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs
How Abacus Life is Transforming Life Insurance into Assets | MarketBeat CEO Series
NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines